医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Morinaga’s Flagship Probiotic Strain BB536 Is Now 100% Gluten-Free

2015年10月02日 AM02:00
このエントリーをはてなブックマークに追加


 

TOKYO

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), the second-largest dairy product company in Japan, announced today that it has completely eliminated gluten from its flagship product, the probiotic strain Bifidobacterium longum Morinaga BB536.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151001005036/en/

On August 2013, the Food and Drug Administration (FDA) issued a final rule defining “gluten-free” for food labeling. The regulation stipulates that for an ingredient or finished product to be labeled “gluten-free,” it must contain less than 20 parts per million (ppm) of gluten. In order to meet market demand for a 100% gluten-free product, Morinaga has now taken the extra step of completely removing all gluten from BB536, thereby surpassing FDA standards.
The new gluten-free version will be introduced at the SupplySide West Global Expo and Conference this October.

“BB536 has been used and trusted by consumers worldwide for more than 30 years,” stated Ko Shiino, General Manager of Morinaga’s International Department. “We are pleased to be able to offer a new, completely gluten-free formulation of this classic probiotic to the marketplace, which will further enhance its value to even the most demanding consumers.”

BB536 is a human residential bifidobacteria (HRB) developed by Morinaga that has numerous benefits for human health. More than 50 human studies show that BB536 provides a natural defense against episodic digestive and abdominal discomforts, including constipation, diarrhea, gas, and bloating. It also improves the ratio of beneficial to harmful bacteria in the body and decreases ammonia and putrefactive products in the digestive tract.

BB536 is manufactured through a unique culturing method that gives it excellent stability, allowing it to be utilized in a wide range of applications, including supplements and functional foods, and in a variety of delivery forms, including capsules, sachets, oils, tablets, powders, chocolates, protein powders, and infant formulas.

Manufacturing BB536 without gluten is just one in a series of improvements Morinaga has undertaken over the past three decades to make the ingredient as market-friendly as possible. “We continually strive to add value to our flagship probiotic strain, whether that’s investing in new clinical research, achieving GRAS certification, or addressing the evolving needs of our consumers, which is our utmost priority,” Shiino explained.

Morinaga also provides technical support for clients who plan to use the company’s probiotics in their products. Morinaga’s technical staff is available to provide raw material handling advice, aid in the development of strain-stable finished products, and help navigate the regulatory maze of various countries to successfully launch new products.

About Morinaga

Morinaga Milk Industry Co., Ltd. is Japan’s second-largest dairy products company. Founded in 1917, Morinaga exhibits excellence in the field of technology and sells not only dairy products but also beneficial functional ingredients isolated from milk. Morinaga has researched and developed several human residential bifidobacteria (HRB).
In addition to Bifidobacterium longum BB536, the company has also developed Bifidobacterium breve M-16V, a strain clinically documented to support the health of infants (including low-birth-weight infants), and a recently launched strain, Bifidobacterium breve B-3 which is currently researched for its potential in healthy weight management.

Please visit our booth at #3770 at SupplySide West, Las Vegas (October 7-8, 2015)

View source version on businesswire.com: http://www.businesswire.com/news/home/20151001005036/en/

CONTACT

Morinaga Milk Industry Co., Ltd.
Midori Koyama, +81-3-3798-0152
International
Department
m-koyama@morinagamilk.co.jp
http://www.morinagamilk.co.jp/english/

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作